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Follicular lymphoma �FL� is the second most com-
mon type of non-Hodgkin lymphoma �NHL� in Western 
Countries� accounting for ��% of all NHL and for ��% 
of all indolent forms� with a median age at diagnosis 
of a�out 6� years [���]. Before the advent of chemo-
therapy� the majority of patients with FL died within 
5 years. With the current therapies� the expected me-
dian survival is approximately ���� years [�]. A�out �5% 
of FL cases have a specific translocation t���;��� that 
leads to the overexpression of the BCL� protein� a mem-
�er of a family of anti-apoptotic proteins� although other 
genetic alterations may �e detected in this su�type 
of lymphoma. As defined �y the WHO� FLs are charac-
terized �y a follicular growth pattern including centro-
cytes �small- to medium-sized cells� and centro�lasts 
�large cells�� and are graded from I to III according to the 
amount of centro�lasts present. The clinical aggressive-
ness of the tumor increases with an increasing num�ers 
of centro�lasts. Grade I is defined �y ≥5 centro�lasts/
high power field �hpf� �follicular small cleaved�� Grade 
II �y 6 to �5 centro�lasts/hpf �follicular mixed�� Grade III 
�y more than �5 centro�lasts/hpf �follicular large cell�. 
Grade III has �een su�divided into Grade IIIa� in which 
centrocytes are present and Grade III�� in which there 
are sheets of centro�lasts. Grade from I to IIIa are 
considered as indolent NHL su�types� while grade III� 
�ehaves as an aggressive lymphoma and is treated 
similarly to a diffuse large B-cell lymphoma [5]. Bone 
marrow involvement is very common �a�out ��% of all 
cases� with paratra�ecular lymphoid aggregates� al-
though other organ involvement is uncommon. FL cells 
express monoclonal immunoglo�ulin �Ig� light chains; 
they are C��9+� C���+� C���+� C���+ and BCL�+� while 
they are negative for C�5 and C���. Clonal Ig gene 
rearrangements are also present and most cases have 
extensive somatic mutations.
In recent decades� the introduction of several treat-
ment options �single alkylating agents� com�ination 
chemotherapy with or without doxoru�icin or fludara�ine� 
total lymphoid irradiation� has improved the overall survival 
�OS� for patients with FL� with complete remission rates 
ranging from 65 to �5% [6]. Fisher et al. demonstrated that 
the introduction of the anti-C��� monoclonal anti�ody 
Rituxima� significantly improved OS [�]. The prognosis 
of FL at diagnosis is currently evaluated on the �asis 
of specific indexes: the Follicular Lymphoma International 
Prognostic Index �FLIPI� considers five prognostic factors� 
including patient age� stage� num�er of involved nodal ar-
eas� serum lactate dehydrogenase and hemoglo�in level 
[�]. It was developed through an international retrospec-
tive study of survival data on ��6� patients with FL diag-
nosed �etween �9�5 and �99�. Currently� FLIPI is a widely 
accepted tool for risk assessment of FL. However� the FLIPI 
has �een designed prior to the era of anti-C��� monoclo-
nal anti�odies and the initial cohort does not represent the 
present course of the disease. More recently� a modified 
version of this scoring system� the FLIPI-�� was proposed 
�y Federico et al. [9] on the �asis of the F� study� in which 
��9� patients �etween January ���� and May ���5 with 
a newly diagnosed FL were registered and 9�� individuals 
receiving treatment were selected as the study popula-
tion. This new prognostic score has� as a target end point� 
progression-free survival �PFS�� considered more realistic 
than OS for a type of lymphoma with a median survival 
likelihood of �� years.
Treatment options are stage-related: while dis-
seminated FL is considered an incura�le disease� with 
a trend to relapse� localized stage FL potentially has 
a different clinical outcome. In fact� it has �een dem-
onstrated that in 5�% of cases it is possi�le to o�tain 
a definitive eradication of the disease. According to the 
current guidelines [��� ��]� stage I�II disease should not 
�e managed with a frontline strategy of watchful waiting� 
radiation therapy representing the gold standard for this 
group of patients: a radiation dose of �� to �6 Gy deliv-
ered in �5 to �� fractions over ��� weeks is associated 
with local control rates of more than 95%. �espite the 
limited stage� BCL2/IgH+ positive cells could �e found 
at diagnosis in the peripheral �lood and/or �one marrow 
of �6 of �� patients �66.6%� �y quantitative PCR and 
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radiotherapy was capa�le of clearing �lood and marrow 
Bcl�+ cells� a response which persisted after a median 
follow-up of ��.5 months [��]. No data are currently 
availa�le concerning the efficacy on PFS of rituxima� 
in localized FL� although rituxima� is capa�le of reduc-
ing the proportion of residual Bcl�+ cells detecta�le 
in the peripheral �lood and/or �one marrow of a propor-
tion of patients following radiotherapy.
In stage III�IV disease� treatment can �e safely de-
ferred without a survival disadvantage if none of the fol-
lowing features occurs: systemic symptoms� high tumor 
�urden� extranodal disease� cytopenia due to marrow in-
volvement� spleen involvement� leukemic phase� serous 
effusions� erythrocyte sedimentation rate > �� mm/h� 
high lactate dehydrogenase levels. A policy of watch-
ful waiting is particularly advisa�le in elderly patients 
�> �� years�. The presumed advantage of a watchful 
waiting approach is that patients are spared the toxic side 
effects of chemotherapy. As already specified� patients 
with advanced and symptomatic FL are treated with the 
expectation that the disease will witness a relapsing and 
remitting course� and may require several lines of treat-
ment during the course of the disease.
For many years� the standard first-line treatment was 
alkylator-�ased� frequently in com�inations including 
vinca alkaloids� anthracyclines or fludara�ine-�ased 
schedules� with similar OS and PFS [��� ��]. More 
recently� several phase III trials have confirmed the 
efficacy of rituxima� in com�ination with an alky lator-
containing regimen� �oth with and without the inclusion 
of anthracyclines [�6� ��]. There is a suggestion that the 
duration of response in patients treated with rituxima� 
and anthracycline-�ased therapies might �e superior 
to that o�tained with less intensive regimens utilizing 
alkylators; a specific randomized trial� FOLL-�5� has 
�een recently conducted in Italy with the aim of dem-
onstrating the most effective first-line therapy in terms 
of OS and PFS for FL �etween the R-CVP� R-CHOP and 
R-FM schedules. Although chemotherapy in com�ina-
tion with rituxima� has improved outcomes in the newly 
diagnosed setting� patients with FL almost always re-
lapse and require a succession of therapies over many 
years. Patients who relapse after a first-line therapy 
not containing either anthracyclines or fludara�ine 
should receive anthracycline- or fludara�ine-�ased 
polychemothe rapy together with rituxima�; patients un-
der the age of 65 with extended relapses after a first-line 
therapy containing either anthracyclines or fludara�ine 
should �e treated with high-dose therapy and au-
tologous stem cell transplant. The same consideration 
should �e made for first-line resistant patients [��].
With regard to new treatment options� Bendamustine 
is a �NA alkylating agent with novel properties� which 
has �een studied in relapsed or rituxima�-refractory 
FL patients [��]. The efficacy of �endamustine is pro�-
a�ly related to its incomplete cross-reactivity with other 
chemotherapeutic agents. Phase II trials of �endamus-
tine in com�ination with rituxima� in relapsed FL have re-
ported an ORRs of 9�% and a median PFS of �� months 
[�9]. Ongoing studies are examining �endamustine with 
�ortezomi�� lenalidomide� temsirolimus� ofatumuma�� 
alemtuzuma� and other novel agents [��� ��]. �ifferent 
maintenance strategies have �een utilized in an attempt 
to prolong PFS in FL. Interferon �IFN� alpha has �een 
used for several years with this aim. A meta-analysis 
of data from the pre-rituxima� era [��] suggests that the 
addition of IFN as maintenance therapy for FL improves 
PFS� while the �enefit on OS is less evident; in a recent 
report� pooled data from different randomized studies 
of the German Low Grade Lymphoma Study Group 
suggest that IFN maintenance prolongs remission 
duration also after rituxima�-containing induction treat-
ments [��]. With regard to rituxima� as maintenance 
treatment� there has �een a growing �ody of evidence 
demonstra ting the clinical advantage of rituxima� main-
tenance therapy following various induction regimens. 
The European Organization for Research and Treat-
ment of Cancer �EORTC� conducted one of the pivotal 
Phase III trials in patients with relapsed or refractory 
FL �EORTC; ���9� trial�. The study demonstrated the 
�enefits of rituxima� maintenance administered every 
three months for two years following chemotherapy 
or immunochemotherapy [��]. An important study 
was conducted using rituxima� as maintenance af-
ter first-line therapy: the results of the PRIMA study 
[�5] indicate that rituxima� maintenance conferred 
significant PFS �enefits �Hazard ratio �.5�; 95% CI: 
�.�9��.6��� �ut no effect on OS was seen. A recent 
meta-analysis �y Vidal et al. [�6] focused on the impact 
on OS of rituxima� maintenance in �oth first line and 
previously treated patients has reported similar results: 
in fact� refractory or relapsed FL patients treated with 
rituxima� maintenance had an improved OS� whereas 
previously untreated patients had no survival �enefit. 
Ongoing studies will define the optimal maintenance 
duration �two years versus five years or until relapse 
or progression�.
Although a large proportion of FL patients respond 
to immunochemotherapy� there is a group of patients 
with resistant/refractory disease for whom there 
is a need for new agents in an attempt to overcome 
the poor prognosis. There are three main groups 
of novel therapeutic agents� as well as other mono-
clonal anti�odies �novel anti-C��� anti�odies such 
as ofatumuma� and GA��� or anti�odies against 
targets other than C����� agents that target signal 
transduction pathways �e.g.� proteasome inhi�itors� 
Bcl-� and Bcl-6 inhi�itors�� microenvironment modula-
tory drugs �immunomodulatory drugs� e.g. lenalido-
mide� [�6���]. Recently� in a phase I trial� GA��� was 
tested in �� resistant or refractory C���+ indolent 
NHL patients [��]: the overall response rate was ��% 
�5 complete responses and � partial responses�. The 
majority of reported adverse events were of grade 
� or �. A similar experience� conducted treating �� re-
lapsed or refractory FL patients with ofatumuma�� 
showed an overall response rate of ��% with a median 
PFS of 5.� months [��]. Upcoming phase III studies will 
demonstrate if targeted therapies can further improve 
the management of patients with FL.
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Research on oncogenic infectious agents� espe-
cially viruses� has helped us to understand the process 
of malignant transformation of cells �ecause the cel-
lular events in viral-driven transformation mirror� often 
�rilliantly� �asic cellular processes that culminate 
in cancer� even those not associated with viruses. In-
fectious agents� especially viruses� account for several 
of the most common malignancies — up to ��% of all 
cancers. Some of these cancers are endemic� with 
a high incidence in certain geographic locations� �ut 
sporadic/lower incidence in other parts of the world. 
Lymphomas arise frequently in association with viruses 
such as Epstein-Barr virus� human herpesvirus � �HHV-
��� human immunodeficiency virus �HIV�� human T-
lymphotropic virus-� �HTLV-��� and hepatitis C virus 
�HCV�. Viruses may contri�ute to lymphomagenesis 
either �y directly infecting the tumor clone �e.g. EBV� 
HHV�� HTLV-��� or via indirect mechanisms altering 
the host immunity �e.g. HIV� or microenvironmental 
interactions �e.g. HCV�.
Gamma-herpesviruses. Two lymphotropic hu-
man gamma herpesviruses can cause� or predispose 
to� lymphoproliferative disorders: Epstein — Barr virus 
�EBV� formally designated as human herpesvirus �� 
and Kaposi sarcoma herpesvirus �KSHV� also called 
human herpesvirus ��. Individuals with inherited or ac-
quired immunodeficiency have a greatly increased risk 
of developing a malignancy caused �y one of these 
two viruses. Specific types of EBV- or HHV-� related 
lymphomas occur predominantly or almost exclusively 
in individuals with HIV infection� transplant recipients 
and children with primary immunodeficiency. Some 
of these diseases� such as Hodgkin and non-Hodgkin 
lymphoma resem�le those occurring in immunocom-
petent patients� �ut the proportion of tumors in which 
EBV is present is increased. Others� like primary ef-
fusion lymphoma and polymorphic post-transplant 
lymphoproliferative disorders� are rarely seen outside 
the context of a specific immunodeficient state.
HIV. The clinical features and natural history of HIV-
associated lymphomas differ greatly from those o�-
served in the general population. The failure to improve 
outcomes with treatment intensification indicates the 
need for the introduction of new therapeutic options. 
HIV-associated lymphomas still represent a relevant 
field of clinical research. Standard methodologies for 
therapy in this patient population have yet to �e esta�-
lished. However� rituxima� plus chemotherapy should 
�e offered to the majority of patients with HIV infection 
and diffuse large B-cell lymphoma and the feasi�ility 
of intensive aggressive chemotherapy regimens has 
�een successfully tested in HIV-associated Burkitt 
lymphomas.
HTLV-I. Adult T-cell leukemia-lymphoma �ATLL� 
is a peripheral T-cell malignancy� closely associated 
with HTLV-� infection. Clinically� ATLL is classified into 
four su�types: acute� lymphoma� chronic and smol-
dering type. Although the prognosis of chronic and 
smoldering-type ATLL is relatively good� that of pa-
tients with acute- or lymphoma-type ATLL still remains 
extremely poor. Zidovudine/IFN-a therapy seems 
to �e promising� although its efficacy has not yet �een 
confirmed in well-designed prospective studies. High-
dose chemotherapy with the support of autologous 
transplantation does not improve outcome. Allogeneic 
stem cell transplantation is promising and approxi-
mately ��% of aggressive ATLL patients are expected 
to survive long-term� although transplantation-related 
mortality is as high as ���5�%.
HCV. HCV is well known for its aetiological role 
in chronic non-A� non-B viral hepatitis� liver cirrhosis 
and hepatocellular carcinoma; in addition� the virus 
has also �een implicated in a num�er of extra-hepatic 
“autoimmune” disease manifestations. A causative 
association �etween HCV and non-Hodgkin lym-
phoma �NHL� was postulated relatively recently and 
has �een the su�ject of intense investigation� as well 
as some de�ate. On the strength of epidemiological 
data� emerging �iological investigations and clini-
cal o�servations� HCV appears to �e involved in the 
pathogenesis of at least a proportion of patients with 
NHL. Morphologically� HCV-associated lymphomas 
represent a variety of histological su�types including 
marginal zone lymphoma �splenic� nodal and extrano-
dal�� small lymphocytic lymphoma/chronic lympho-
cytic leukaemia� lymphoplasmacytic lymphoma and 
diffuse large B-cell lymphoma. Remarka�ly� some 
HCV-associated NHL appear to �e highly responsive 
to antiviral therapy� providing some clinical evidence 
for this relationship� as well as the prospect for novel 
therapeutic intervention.
Perspectives. Some virus-related lymphomas 
may �e difficult to treat with conventional approaches. 
�espite recent advancements using cytotoxic� lym-
phoma-specific� and adoptive therapies� the long-term 
outcome of patients with y-herpesvirus lymphomas 
occurring in severely immunocompromised patients 
and ATLL continues to �e poor. Lytic-inducing thera-
pies targeting NF-kB, and viral and tumor cell epigen-
etic mechanisms afford the advantage of exploiting the 
intrinsic presence of oncogenic viruses to eradicate 
infected tumor cells. On these grounds� novel clinical 
approaches targeting viral latency are currently �eing 
investigated.
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